Trial reportInternational journal of impotence research2004
Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study.
Trial report in International journal of impotence research, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Colchicine for the primary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2025Pooled it
- A systematic review of non-surgical management in Peyronie's disease.International journal of impotence research · 2023Pooled it
- Non-surgical therapies for Peyronie's disease.The Cochrane database of systematic reviews · 2023Pooled it
- [Assessment among German urologists of various conservative treatment modalities for Peyronie's disease. Results of a survey].Der Urologe. Ausg. A · 2005Trial
- Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study.International journal of impotence researchTrial
- Contemporary Management Strategies for Peyronie's Disease: A Comprehensive Review.Research and reports in urology · 2026Review
- Acute Phase Peyronie's Disease: Where Do We Stand?Cureus · 2024Review
- Conservative treatment of Peyronie's disease: a guide.World journal of urology · 2024Review
- Trends in treatment of Peyronie's disease in adult men in the United States from 2008 to 2017-results from an encounter and claims database.International journal of impotence research · 2022Article
- Minimally invasive therapies for Peyronie's disease: the current state of the art.Translational andrology and urology · 2020Review
- Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie's Disease.Sexual medicine · 2019Article
- Medical Management of Peyronie's Disease: Review of the Clinical Evidence.Medical sciences (Basel, Switzerland) · 2019Review
- Nonsurgical management of Peyronie's disease.Nature reviews. Urology · 2019Review
- Beyond Curvature: Prevalence and Characteristics of Penile Volume-Loss Deformities in Men With Peyronie's Disease.Sexual medicine · 2018Article
- Contemporary Review of Peyronie's Disease Treatment.Current urology reports · 2018Review
- Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction.Translational andrology and urology · 2017Review
- Oral therapy for Peyronie's disease, does it work?Translational andrology and urology · 2016Review
- A review of the epidemiology and treatment of Peyronie's disease.Research and reports in urology · 2016Review
- Colchicine--Update on mechanisms of action and therapeutic uses.Seminars in arthritis and rheumatism · 2015Review
- PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.Current sexual health reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine effectiveness and safety of colchicine in Peyronie's disease. In all, 84 patients with Peyronie's disease who did not have calcified plaque were entered into study. The mean disease duration was 15 months. A medical history was obtained, and physical examination, penile X-ray, and dynamic penile duplex ultrasound were performed. Patients were randomly divided into group 1, those who received 0.5-2.5 mg colchicine daily for 4 months and group 2, who received placebo for the same period. Response to therapy was assessed objectively, during dynamic penile duplex ultrasound, as well as subjectively using International Index of Erectile Function (IIEF) questionnaire and measurements of pain, duration of disease, penile curvature, and plaque size. Differences before and after treatment and among the three Kelami classification groups were assessed. In total, 78 (92.8%) completed the whole treatment schedule. Pain resolved in 60 and 63.6% of the patients treated with colchicine and placebo, respectively (P > 0.05). After therapy, in subjects and controls a reduction in the penile deformity was observed by 17.1 and 18.4% of the patients (P > 0.05), and a decrease in plaque size was noticed by 10.5 and 10%, respectively (P > 0.05). Objective measurements did not demonstrate any difference in plaque size or penile curvature. There were no substantial differences in response to treatment based on duration of disease or within the three Kelami classification groups. Significant drug-related adverse effects occurred in colchicine group and in two cases was treatment discontinued. Colchicine is no better than placebo in improvement of pain, curvature angle, or plaque size in patients with Peyronie's disease.
Indexed as
Identifiers
14973528What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.